LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Aktien・Fate Therapeutics Inc

Fate Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

0.96

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.92

Max

0.98

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.6M -34M
Verkäufe	278K 1.9M
Gewinnspanne	-1,786.576
Angestellte	181
EBITDA	979K -37M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+334.02% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	10. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	13M 120M
Vorheriger Eröffnungskurs	0.96
Vorheriger Schlusskurs	0.96

Nachrichtenstimmung

By Acuity

88%

12%

358 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

0.9101 / 1.14 Unterstützung & Widerstand

Fate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2025, 23:59 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. Sept. 2025, 22:02 UTC

Wichtige Markttreiber

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Tron Shares Rise After New Investment From Bravemorning

8. Sept. 2025, 16:14 UTC

Wichtige Markttreiber

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. Sept. 2025, 16:13 UTC

Wichtige Markttreiber

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. Sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. Sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. Sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. Sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. Sept. 2025, 21:47 UTC

Wichtige Markttreiber

Microsoft Signs $17.4B AI Deal With Nebius

8. Sept. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. Sept. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. Sept. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. Sept. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. Sept. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. Sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. Sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. Sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. Sept. 2025, 16:59 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. Sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. Sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 16:16 UTC

Ergebnisse

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Fate Therapeutics Inc Prognose

Kursziel

By TipRanks

334.02% Vorteil

12-Monats-Prognose

Durchschnitt 4.21 USD 334.02%

Hoch 7 USD

Tief 2 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fate Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Fate Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

0.9101 / 1.14Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Stimmung

By Acuity

358 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.